Galpin/DA/N2 IIIBenv 
LIST OF FIGURES 
Figure 1 Derivation of HIV-1 IIIBenv/rev Retroviral Provector (N2 IIIBenv) 34 
Figure 2 DA/N2 IIIBenv. 2C3 Northern Analysis with Neomycin and (3-Actin 
Probes 35 
Figure 3 Expression of HIV-1 env in HIV-IT (V) Transduced Human Cells 36 
Figure 4 HIV-IT (V) Transduction of Transformed and Primary Cell Lines from 
Different Species 37 
Figure 5 Vector Producing Cell Line - DA/N2 IIIBenv. 2C3 QC Testing Master Cell 
Bank 38 
Figure 6 Events Required for Potential Generation of Replication-Competent Retrovirus 
from the Producer Cell Line (DA/N2 IIIBenv. 2C3) 39 
Figure 7 Mus dunni Cocultivation/Marker Rescue Assay Results of Spiking 
Experiments 40 
Figure 8 Cumulative Data on CTL Induction by HIV-IT (V) in Mice 41 
Figure 9A Direct Vector Induced CTL: One Injection Dosing 42 
Figure 9B Direct Vector Induced CTL: Two Injection Dosing 42 
Figure 10 Direct Vector Induced CTL: Specificity 43 
Figure 1 1 Crossreactivity of Direct Vector-Induced CTL 44 
Figure 12 Specificity of Direct Vector- Induced CTL 45 
Figure 13 BCenv-Induced CTL Lysis of HIV-Infected Target Cells 46 
Figure 14A BCenv-Induced CTL Lysis of Human Targets HIV-1 Clinical Isolates 47 
Figure 14B CTL Lysis of HIV-Infected Targets: Sequential HIV Patient Isolates 47 
Figure 1 5 Direct Vector Induced gp 1 20 Antibody 48 
Figure 16 Rhesus Monkey CTL Induction: Direct Vector Injection 49 
Figure 17 PCR Analysis of HIV-IT Provector Integration 50 
Figure 18 CTL Patient Responses in Assays with and without Restimulation In Vitro 5 1 
Figure 19 Lysis of Peptide Coated Patient Targets 52 
Recombinant DNA Research, Volume 17 
[863] 
